Overview
Background
Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.
Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Qualifications
- Masters (Coursework) of Medical Science, University of Newcastle
- Royal Australasian College of Physicians, Royal Australasian College of Physicians
- Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia
Research impacts
The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.
Works
Search Professor Peter Mollee’s works on UQ eSpace
2020
Journal Article
Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis
Kastritis, Efstathios, Leleu, Xavier, Arnulf, Bertrand, Zamagni, Elena, Cibeira, Maria Teresa, Kwok, Fiona, Mollee, Peter, Hajek, Roman, Moreau, Philippe, Jaccard, Arnaud, Schonland, Stefan O., Filshie, Robin, Nicolas-Virelizier, Emmanuelle, Augustson, Bradley, Mateos, Maria-Victoria, Wechalekar, Ashutosh, Hachulla, Eric, Milani, Paolo, Dimopoulos, Meletios A., Fermand, Jean-Paul, Foli, Andrea, Gavriatopoulou, Maria, Klersy, Catherine, Palumbo, Antonio, Sonneveld, Pieter, Erik Johnsen, Hans, Merlini, Giampaolo and Palladini, Giovanni (2020). Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. Journal of Clinical Oncology, 38 (28), 3252-3260. doi: 10.1200/JCO.20.01285
2020
Journal Article
Catheter-associated bloodstream infections in adults with cancer: a prospective randomized controlled trial
Mollee, P., Okano, S., Abro, E., Looke, D., Kennedy, G., Harper, J., Clouston, J., Van Kuilenburg, R., Geary, A., Joubert, W., Eastgate, M. and Jones, M. (2020). Catheter-associated bloodstream infections in adults with cancer: a prospective randomized controlled trial. Journal of Hospital Infection, 106 (2), 335-342. doi: 10.1016/j.jhin.2020.07.021
2020
Journal Article
HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients
Burgess, M., Chen, U. C. E., Mapp, S., Blumenthal, A., Mollee, P., Gill, D. and Saunders, N. A. (2020). HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients. Oncogene, 39 (35), 5756-5767. doi: 10.1038/s41388-020-01394-w
2020
Journal Article
Identifying an obinutuzumab resistant subpopulation of monocyte-derived-macrophages from patients with CLL
Burgess, Melinda, Chen, Yu Chen Enya, Mapp, Sally, Mollee, Peter, Gill, Devinder and Saunders, Nicholas A. (2020). Identifying an obinutuzumab resistant subpopulation of monocyte-derived-macrophages from patients with CLL. Leukemia and Lymphoma, 61 (11), 1-5. doi: 10.1080/10428194.2020.1775211
2020
Journal Article
Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance
Weinkove, Robert, McQuilten, Zoe K, Adler, Jonathan, Agar, Meera R, Blyth, Emily, Cheng, Allen C, Conyers, Rachel, Haeusler, Gabrielle M, Hardie, Claire, Jackson, Christopher, Lane, Steven W, Middlemiss, Tom, Mollee, Peter, Mulligan, Stephen P, Ritchie, David, Ruka, Myra, Solomon, Benjamin, Szer, Jeffrey, Thursky, Karin A, Wood, Erica M, Worth, Leon J, Yong, Michelle K, Slavin, Monica A and Teh, Benjamin W (2020). Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. Medical Journal of Australia, 212 (10) mja2.50607, 481-489. doi: 10.5694/mja2.50607
2020
Journal Article
Bortezomib use and outcomes for the treatment of multiple myeloma
Loke, Crystal, Mollee, Peter, McPherson, Ian, Walpole, Euan, Yue, Mimi, Mutsando, Howard, Wong, Phillip, Weston, Helen, Tomlinson, Ross and Hollingworth, Samantha (2020). Bortezomib use and outcomes for the treatment of multiple myeloma. Internal Medicine Journal, 50 (9) imj.14886, 1059-1066. doi: 10.1111/imj.14886
2020
Journal Article
A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group
Maqbool, M. Gohar, Tam, Constantine S., Morison, Ian M., Simpson, David, Mollee, Peter, Schneider, Hans, Chan, Henry, Juneja, Surender, Harvey, Yasmin, Nath, Lakshmi, Hissaria, Pravin, Prince, H. Miles, Wordsworth, Helen, Opat, Stephen and Talaulikar, Dipti (2020). A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology, 52 (2), 167-178. doi: 10.1016/j.pathol.2019.11.002
2020
Journal Article
Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolome
Mohamed, Ahmed, Collins, Joel, Jiang, Hui, Molendijk, Jeffrey, Stoll, Thomas, Torta, Federico, Wenk, Markus R., Bird, Robert J., Marlton, Paula, Mollee, Peter, Markey, Kate A. and Hill, Michelle M. (2020). Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolome. PloS One, 15 (1) e0227455, e0227455. doi: 10.1371/journal.pone.0227455
2020
Conference Publication
Changing picture of ATTR wild type cardiomyopathy in Australia – Queensland Amyloidosis Centre experience
Korczyk, D., Woodcroft-Brown, V., Maffey, M. and Mollee, P. (2020). Changing picture of ATTR wild type cardiomyopathy in Australia – Queensland Amyloidosis Centre experience. 68th Cardiac Society of Australia and New Zealand Annual Scientific Meeting, the International Society for Heart Research Australasian Section Annual Scientific Meeting and the 14th Annual Australia and New Zealand Endovascular Therapies Meeting, Online, 11-13 December 2020. Chatswood, NSW Australia: Elsevier. doi: 10.1016/j.hlc.2020.09.100
2020
Conference Publication
99Tc-DPD Bone scintigraphy correlates with left ventricular wall thickness and global longitudinal strain in patients with ATTR wild type cardiac amyloidosis
Robinson, J., Burrage, M., Ngai, S., Mackenzie, E., Duong, J., Mollee, P. and Korczyk, D. (2020). 99Tc-DPD Bone scintigraphy correlates with left ventricular wall thickness and global longitudinal strain in patients with ATTR wild type cardiac amyloidosis. 68th Cardiac Society of Australia and New Zealand Annual Scientific Meeting, the International Society for Heart Research Australasian Section Annual Scientific Meeting and the 14th Annual Australia and New Zealand Endovascular Therapies Meeting, Online, 11-13 December 2020. Chatswood, NSW Australia: Elsevier. doi: 10.1016/j.hlc.2020.09.069
2019
Journal Article
Trends in myeloma relative survival in Queensland by treatment era, age, place of residence, and socioeconomic status
Harwood, Matthew, Dunn, Nathan, Moore, Julie, Mollee, Peter and Hapgood, Greg (2019). Trends in myeloma relative survival in Queensland by treatment era, age, place of residence, and socioeconomic status. Leukemia & Lymphoma, 61 (3), 1-7. doi: 10.1080/10428194.2019.1688322
2019
Journal Article
Combination bone marrow imaging using positron emission tomography (PET)-MRI in plasma cell dyscrasias: correlation with prognostic laboratory values and clinicopathological diagnosis
Tate, Courtney J., Mollee, Peter N. and Miles, Kenneth A. (2019). Combination bone marrow imaging using positron emission tomography (PET)-MRI in plasma cell dyscrasias: correlation with prognostic laboratory values and clinicopathological diagnosis. BJR|Open, 1 (1), 20180020. doi: 10.1259/bjro.20180020
2019
Conference Publication
Significantly improved relative survival of patients with myeloma in Queensland with treatment advances
Mollee, Peter, Harwood, Matthew, Dunn, Nathan, Moore, Julie and Hapgood, Greg (2019). Significantly improved relative survival of patients with myeloma in Queensland with treatment advances. 17th International Myeloma Workshop, Boston, MA, 12-15 September 2019. Dallas: CIG Media Group. doi: 10.1016/j.clml.2019.09.387
2019
Conference Publication
Development of an individualized, supervised exercise intervention as standard care for patients with multiple Myeloma
Nicol, Jennifer, Woodrow, Carmel, Burton, Nicola, Hill, Michelle, Skinner, Tina, Mollee, Peter and Nicol, Andrew (2019). Development of an individualized, supervised exercise intervention as standard care for patients with multiple Myeloma. 17th International Myeloma Workshop, Boston, MA United States, 12-15 September 2019. New York, NY United States: Elsevier . doi: 10.1016/j.clml.2019.09.355
2019
Conference Publication
Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction
Mollee, Peter, Boyle, Stephen, Wellard, Cameron, Moore, Elizabeth, Blacklock, Hilary, Harrison, Simon J., Ho, P. Joy, Hocking, Jay, McQuilten, Zoe, Quach, Hang, Spearing, Ruth, Wood, Erica and Spencer, Andrew (2019). Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction. 17th International Myeloma Workshop, Boston, MA United States, 12 - 15 September 2019. New York, NY United States: Elsevier. doi: 10.1016/j.clml.2019.09.388
2019
Conference Publication
Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
Blacklock, Hilary, Moore, Elizabeth, Wellard, Cameron, Harrison, Simon J., Ho, P. Joy, Hocking, Jay, McQuilten, Zoe, Mollee, Peter, Quach, Hang, Spearing, Ruth, Wood, Erica and Spencer, Andrew (2019). Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). 17th International Myeloma Workshop, Boston, MA, 12-15 September 2019. Dallas: CIG Media Group. doi: 10.1016/j.clml.2019.09.354
2019
Conference Publication
Daratumumab, lenalidomide, and dexamethasone (d-rd) delivers a reduction and delay in worsening of pain symptoms for patients with newly diagnosed multiple myeloma ineligible for transplant
Gries, Katharine, Facon, Thierry, Plesner, Torben, Usmani, Saad, Kumar, Shaji, Orlowski, Robert Z., Bahlis, Nizar J., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, Hulin, Cyrille, Weisel, Katja, He, Jianming, Ho, Kai Fai, Wang, Jim, Van Rampelbergh, Rian, Uhlar, Clarissa, Kobos, Rachel and Perrot, Aurore (2019). Daratumumab, lenalidomide, and dexamethasone (d-rd) delivers a reduction and delay in worsening of pain symptoms for patients with newly diagnosed multiple myeloma ineligible for transplant. 17th International Myeloma Workshop, Boston, MA, 12-15 September 2019. Dallas: CIG Media Group. doi: 10.1016/j.clml.2019.09.375
2019
Journal Article
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance
Tobin, Joshua W. D., Rule, Gabrielle, Colvin, Katherine, Calvente, Lourdes, Hodgson, David, Bell, Stephen, Dunduru, Chengetai, Gallo, James, Tsang, Erica S., Tan, Xuan, Wong, Jonathan, Pearce, Jessica, Campbell, Robert, Tneh, Shao, Shorten, Sophie, Ng, Melissa, Cochrane, Tara, Tam, Constantine S., Abro, Emad, Hawkes, Eliza, Hodges, Georgina, Kansara, Roopesh, Talaulikar, Dipti, Gilbertson, Michael, Johnston, Anna M., Savage, Kerry J., Villa, Diego, Morris, Kirk, Ratnasingam, Sumi ... Hapgood, Greg (2019). Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Advances, 3 (19), 2804-2811. doi: 10.1182/bloodadvances.2019000458
2019
Journal Article
Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration
Tobin, Joshua W. D., Keane, Colm, Gunawardana, Jay, Mollee, Peter, Birch, Simone, Hoang, Thanh, Lee, Justina, Li, Li, Huang, Li, Murigneux, Valentine, Fink, J. Lynn, Matigian, Nicholas, Vari, Frank, Francis, Santiyagu, Kridel, Robert, Weigert, Oliver, Haebe, Sarah, Jurinovic, Vindi, Klapper, Wolfram, Steidl, Christian, Sehn, Laurie H., Law, Soi-Cheng, Wykes, Michelle N. and Gandhi, Maher K. (2019). Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration. Journal of Clinical Oncology, 37 (34), 3300-3309. doi: 10.1200/JCO.18.02365
2019
Journal Article
Renal impairment at diagnosis in myeloma: Patient characteristics, treatment, and impact on outcomes. Results trom the Australia and New Zealand myeloma and related diseases registry
Ho, P. Joy, Moore, Elizabeth M., McQuilten, Zoe K., Wellard, Cameron, Bergin, Krystal, Augustson, Bradley, Blacklock, Hilary, Harrison, Simon J., Horvath, Noemi, King, Tracy, Mollee, Peter, Quach, Hang, Reid, Christopher, Rosengarten, Brian, Walker, Patricia, Wood, Erica M. and Spencer, Andrew (2019). Renal impairment at diagnosis in myeloma: Patient characteristics, treatment, and impact on outcomes. Results trom the Australia and New Zealand myeloma and related diseases registry. Clinical Lymphoma, Myeloma and Leukemia, 19 (8), e415-e424. doi: 10.1016/j.clml.2019.05.010
Supervision
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Master Philosophy
Novel Radionuclide Tracers for Imaging in Amyloidosis
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
Doctor Philosophy
Addressing frailty in older people with haematological malignancies
Associate Advisor
Other advisors: Associate Professor Emily Gordon, Dr Natasha Reid, Professor Ruth Hubbard
Media
Enquiries
For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team: